Core Viewpoint - The article discusses the approval of the first domestic ADC (antibody-drug conjugate) for treating HER2 low-expressing breast cancer with liver metastasis in China, highlighting its significance in addressing unmet clinical needs in this patient population [2][3]. Group 1: Product Approval and Market Impact - Rongchang Biopharma's ADC, Vidisicimab (brand name: Aidiqi®), has received approval from the National Medical Products Administration for a new indication, making it the first domestic ADC approved for this specific condition [2]. - This approval expands the treatment options for breast cancer patients in China, particularly for those with HER2 low expression and liver metastasis, which has a poor prognosis [3]. - Breast cancer is the most common malignant tumor among women in China, with approximately 357,000 new cases annually, and 45% to 55% of these patients are HER2 low expressers [3]. Group 2: Clinical Trials and Efficacy - The approval is based on a randomized, open-label, parallel-controlled, multi-center Phase III clinical trial (RC48-C012), which demonstrated good efficacy and safety of Vidisicimab in patients with advanced breast cancer who had previously received systemic treatment [4]. - Vidisicimab is recognized as China's first original ADC drug and has received dual breakthrough therapy designation from both the FDA and the National Medical Products Administration [4]. Group 3: Financial Projections and Growth - Rongchang Biopharma anticipates total revenue of approximately 3.25 billion yuan in 2025, representing an increase of about 89% year-on-year, with a projected net profit of approximately 716 million yuan, marking a turnaround to profitability [4]. - The commercial performance of Vidisicimab is becoming a core growth engine for the company's financial results, indicating strong market demand and potential for future revenue growth [4].

Financial Data and Key Metrics Changes - In 2025, the company reported total revenue of CNY 2.06 billion, a 6.5% increase compared to the previous year, with commercialized revenue at CNY 540 million [45][46] - Gross margin increased by 16.1% to CNY 1.47 billion, benefiting from a favorable income mix [46][47] - Total loss for the year was CNY 380 million, slightly higher than the previous year, attributed to increased marketing and sales expenses due to the first year of commercialization [47][48] Business Line Data and Key Metrics Changes - The company has four products launched with multiple indications, marking the first year of complete commercialization [22][31] - The commercialization team has expanded to nearly 600 people, covering over 300 cities and 1,200 medical institutions in China [12][22] - The company has successfully included three products in the national reimbursement catalog (NRDL) [27][28] Market Data and Key Metrics Changes - The company has established partnerships with major distributors, accounting for 90% of its business, and expanded its presence in over 400 professional pharmacies [28][29] - The commercialization strategy focuses on brand building and expanding access to hospitals and pharmacies, with a goal to double sales in 2026 [22][67] Company Strategy and Development Direction - The company aims to advance its differentiated pipeline and address unmet clinical needs while optimizing its ADC platform [20][64] - Strategic collaborations are emphasized to enhance the value of the pipeline and expand commercial partnerships globally [10][20] - The focus is on developing new targets and integrating ADC with immunotherapy for enhanced efficacy [17][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving significant growth in commercialization, particularly after successful NRDL negotiations [68] - The company anticipates that NRDL revenue will account for over 80% of total revenue in the coming year [67] - The management highlighted the importance of building a strong commercial team to navigate the competitive landscape [22][68] Other Important Information - The company has a robust pipeline with over 30 R&D projects, including several in clinical development stages [6][10] - The company raised $250 million through H-share placement in 2025, enhancing its cash reserves to CNY 4.6 billion [13][52] Q&A Session Questions and Answers Question: What is the timeline for data availability on first-line lung cancer trials? - Management indicated that data for the first-line trials may be available by Q4 this year during the ASCO meeting [55][59] Question: What is the expected revenue from licensing and how does it relate to R&D expenses? - Management clarified that licensing revenue is accounted for differently and does not correspond directly to R&D expenses [70] Question: How will the staffing for breast cancer and lung cancer teams be adjusted? - The company plans to increase staffing for the lung cancer team due to its larger patient population, while maintaining a separate focus for breast cancer [72]

2025 ANNUAL RESULTS PRESENTATION 2025年度业绩演示材 料 MARCH 2026 202 6年 3月 1 DISCLAIMER 免责声明 The information contained in this presentation is intended solely for your personal reference. Such information is subject to change without notice and no representation or warranty express or implied is made as to, and no reliance, should be placed on, the fairness, accuracy, completeness or correctness of the information contained in this presentation. This presentation does not intend to provide, and you may not rely on ...

Core Viewpoint - SHR-A1811, a novel HER2-targeting antibody-drug conjugate (ADC) developed by Suzhou Merrion Biopharmaceuticals, shows significant antitumor activity and safety in advanced solid tumor patients who have undergone extensive prior treatments [2][11]. Group 1: Clinical Development and Efficacy - The global phase 1 trial of SHR-A1811 demonstrated long-term efficacy and good safety in patients with advanced solid tumors, including breast cancer, cholangiocarcinoma, and urothelial carcinoma [2][11]. - The trial involved 396 patients who had previously received 2-4 treatment regimens, with a median follow-up of 17.1 months for HER2-positive breast cancer patients [8]. - The median progression-free survival (PFS) was reported as 25.0 months for HER2-positive breast cancer patients and 11.0 months for HER2 low-expressing breast cancer patients [8]. Group 2: Safety Profile - The safety profile of SHR-A1811 was consistent with previous reports, with 65.9% of patients experiencing grade 3 or higher treatment-related adverse events [8]. - Only 2.5% of patients experienced any level of interstitial lung disease, indicating a relatively low risk associated with this treatment [8]. Group 3: Mechanism and Advantages - SHR-A1811 combines trastuzumab with a cleavable linker and a topoisomerase I inhibitor, showing superior membrane permeability and cytotoxicity compared to T-DXd [6]. - The drug exhibits a good safety profile with a drug-to-antibody ratio of 6 and a low release rate of toxic payloads, suggesting its potential as a safer alternative in HER2-targeted therapies [6][11].

Core Viewpoint - A new preoperative adjuvant therapy significantly extends survival time for patients with intrahepatic cholangiocarcinoma, highlighting China's innovative drug development capabilities in the medical field [3][4][5]. Group 1: Research Findings - The study conducted by the team at Fudan University Zhongshan Hospital demonstrated that patients receiving three cycles of GEMOX chemotherapy combined with targeted drug Lenvatinib and immunotherapy drug Toripalimab had a median survival time of 18 months, compared to 8.7 months in the control group [4]. - The median recurrence-free survival for patients in the treatment group was 15.4 months, significantly better than the control group's 9.7 months, with a 31% reduction in recurrence risk [4][5]. - This research is the first multicenter, randomized controlled trial exploring neoadjuvant therapy for intrahepatic cholangiocarcinoma, filling an international gap and showcasing China's leading position in liver cancer treatment [5]. Group 2: Drug Development and Innovation - The PD-1 inhibitors used in the studies are original drugs developed by Chinese biopharmaceutical companies, with Camrelizumab from Heng Rui Medicine and Toripalimab from Junshi Biosciences, both included in medical insurance [6]. - In 2025, China is expected to see a surge in innovative pharmaceutical achievements, with a record 76 innovative drugs approved by the National Medical Products Administration, over 80% of which are domestically developed [6]. - The Chinese biopharmaceutical industry is recognized as a key indicator of national technological innovation and comprehensive strength, with significant advancements in tumor immunotherapy and other cutting-edge fields [6][7]. Group 3: Industry Challenges and Recommendations - Despite the progress, there is a call for enhancing original innovation capabilities to produce more globally influential results and to strengthen intellectual property protection [7]. - Recommendations include direct inclusion of innovative drugs in medical institution drug directories without hospital admission thresholds, ensuring efficient application of insurance-covered innovative drugs [7].

Core Viewpoint - The approval of the new indication for TROP2 ADC drug Sacituzumab (sac-TMT) marks a significant advancement in the treatment of HR+/HER2- breast cancer, highlighting its clinical value and market urgency [1][5][13]. Group 1: Drug Approval and Indications - Sacituzumab has been approved for treating adults with unresectable locally advanced or metastatic HR+ and HER2- breast cancer who have previously received endocrine therapy and other systemic treatments [1][5]. - The approval is based on positive data from the OptiTROP-Breast02 Phase III study, which demonstrated significant survival benefits and manageable safety in a difficult-to-treat patient population [7][13]. Group 2: Drug Characteristics and Development - Sacituzumab is an innovative ADC targeting TROP2, composed of a humanized monoclonal antibody, a cleavable linker, and a novel topoisomerase I inhibitor, with a drug-antibody ratio (DAR) of 7.4, indicating strong drug delivery capabilities [5]. - The drug has multiple approved indications, including treatment for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) [5][6]. Group 3: Global Collaboration and Market Strategy - In May 2022, a strategic collaboration was established with MSD, granting exclusive rights for development and commercialization of Sacituzumab outside Greater China, indicating a global expansion strategy [8]. - MSD has initiated 16 global Phase III clinical studies across various cancer types, aiming to position Sacituzumab as a broad-spectrum ADC [8]. Group 4: Competitive Landscape - Currently, three TROP2 ADCs have been approved globally, including Sacituzumab, highlighting the competitive nature of the ADC market [9]. - In the domestic market, in addition to Sacituzumab, three other products are in Phase III clinical trials, intensifying competition [10]. Group 5: Market Demand and Future Outlook - HR+/HER2- breast cancer accounts for approximately 70% of all breast cancer cases, with significant unmet clinical needs due to treatment resistance and multiple lines of therapy failures [13]. - The approval of Sacituzumab not only enhances treatment options for this patient population but also strengthens the position of domestic ADCs in the international market [13][14]. - The future of the ADC industry will focus on maintaining first-mover advantages, expanding combination therapies, and improving patient accessibility [14].

Core Viewpoint - China Biologic Products (01177) announced that its wholly-owned subsidiary, Lixin Pharmaceutical Technology (Shanghai) Co., Ltd., has initiated a Phase III registration clinical trial for its self-developed innovative drug, LM-302, targeting CLDN18.2-positive advanced gastric and gastroesophageal junction adenocarcinoma [1][2]. Group 1: Clinical Development - LM-302 is the first CLDN18.2 antibody-drug conjugate (ADC) to complete patient enrollment in a Phase III clinical trial globally [1]. - The drug specifically targets CLDN18.2-positive tumor cells, delivering a small molecule toxin to achieve precise tumor cell destruction [1]. - The ongoing Phase III trial focuses on patients with locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma who have received three or more prior lines of therapy [2]. Group 2: Clinical Results - At the 2025 American Society of Clinical Oncology (ASCO) annual meeting, Lixin Pharmaceutical reported that in 41 evaluable patients, the objective response rate (ORR) was 65.9% and the disease control rate (DCR) was 85.4% [2]. - Among 32 patients with CLDN18.2 expression ≥25%, the ORR reached 71.9% and the DCR was 96.9% [2]. - The study also indicated that for patients with PD-L1 CPS <1, the ORR was 63.3%, while for those with CPS ≥1, the ORR was 77.8% [2]. Group 3: Future Plans and Regulatory Status - In addition to the ongoing Phase III study, LM-302 is set to undergo another Phase III registration trial in China, focusing on first-line treatment for CLDN18.2-positive locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma [2]. - LM-302 has been included in the breakthrough therapy designation by the China National Medical Products Administration (NMPA) and has received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) [2]. Group 4: Company Strategy - Leveraging strong resources and industrial capabilities, Lixin Pharmaceutical is accelerating the clinical translation and commercialization of more innovative drugs, aiming to provide accessible treatment options for global cancer patients [3].

Core Viewpoint - China Biologic Products (01177) announced that its wholly-owned subsidiary, Lixin Pharmaceutical Technology (Shanghai) Co., Ltd., has initiated a Phase III registration clinical trial for its innovative drug, LM-302, targeting CLDN18.2 positive advanced gastric and gastroesophageal junction adenocarcinoma, marking it as the first CLDN18.2 ADC drug to complete patient enrollment in a Phase III trial [1][2]. Group 1 - LM-302 is an antibody-drug conjugate (ADC) that specifically targets CLDN18.2 positive tumor cells, delivering a small molecule toxin to achieve precise tumor cell destruction [1]. - The drug shows promising clinical development potential in various gastrointestinal tumors, including gastric cancer, pancreatic cancer, and cholangiocarcinoma, and aims to provide new treatment options for patients with low CLDN18.2 and PD-L1 expression [1][2]. - At the 2025 ASCO annual meeting, Lixin Pharmaceutical reported an objective response rate (ORR) of 65.9% and a disease control rate (DCR) of 85.4% in 41 evaluable patients, with even higher rates in patients with CLDN18.2 expression ≥25% [2]. Group 2 - In addition to the ongoing Phase III study for advanced gastric cancer, LM-302 is set to undergo another Phase III trial in China, combining it with PD-1 monoclonal antibodies for first-line treatment of CLDN18.2 positive advanced gastric cancer [2]. - Multiple indications for LM-302 have been designated as breakthrough therapies by the China National Medical Products Administration (NMPA) and have received orphan drug designation from the U.S. FDA [2]. - Lixin Pharmaceutical is accelerating the clinical transformation and commercialization of more innovative drugs, aiming to provide accessible treatment options for global cancer patients [3].

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 四川科倫博泰生物醫藥股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6990） 自願公告 核心產品TROP2 ADC蘆康沙妥珠單抗(sac-TMT) 獲 國 家 藥 品 監 督 管 理 局 批 准 第 四 項 適 應 症 上 市， 用於治療2L+ HR+/HER2-乳腺癌 四 川 科 倫 博 泰 生 物 醫 藥 股 份 有 限 公 司（「本公司」）董 事（「董 事」）董 事 會（「董 事 會」）欣 然 宣 佈，近 日，本 公 司 靶 向 人 滋 養 細 胞 表 面 抗 原2(TROP2)的抗體 偶聯藥物(ADC)蘆 康 沙 妥 珠 單 抗（sac-TMT，亦稱SKB264/MK-2870）（佳 泰 萊®） 的一項新增適應症上市申請 已獲中國國家藥品監督管理局(NMPA)批 准， 用於治療既往接受過內分泌治療且在晚期疾病階段接受過至少一線化療 的不可切除或轉移性的激素受體陽性(HR+)且人類表皮生長因子受體2陰 性（HER2-）（免 疫 組 織 化 ...

Investment Rating - The industry rating is "Neutral" for the biopharmaceutical sector, indicating a balanced outlook with expected returns in line with the market [3][9]. Core Insights - The report highlights that Daiichi Sankyo's ADC drug R-DXd has received breakthrough therapy designation in China for treating platinum-resistant ovarian cancer, primary peritoneal cancer, or fallopian tube cancer in adults who have previously received bevacizumab [5]. - The pharmaceutical sector experienced a decline of 0.42% on January 22, 2025, underperforming the CSI 300 index by 0.43 percentage points, ranking 29th among 31 sub-industries [4]. - Key performers in the market included offline pharmacies (+1.70%), pharmaceutical distribution (+0.90%), and hospitals (+0.40%), while other biopharmaceuticals (-1.08%) and medical device sectors (-0.44%) lagged [4]. Summary by Sections Market Performance - On January 22, 2025, the pharmaceutical sector's performance was -0.42%, underperforming the CSI 300 index by 0.43 percentage points, with offline pharmacies and medical distribution showing positive growth [4]. Company News - Boteng Co. (300363) expects revenue of 3.35-3.50 billion yuan in 2025, a year-on-year increase of 11%-16%, with a net profit forecast of 80-105 million yuan [6]. - Jinkai Technology (688356) anticipates revenue of 315 million yuan in 2025, a growth of 38.71%, with net profit expected to reach 60-66 million yuan, reflecting a significant increase of over 100% [6]. - Yiling Pharmaceutical (002603) projects a net profit of 1.20-1.30 billion yuan for 2025, indicating a turnaround from losses in the previous year [6].